Diagnosis and Treatment of Primary Biliary Cholangitis

Diagnostic Considerations

A positive antimitochondrial antibody (AMA) titer of 1:80 most likely indicates Primary Biliary Cholangitis (PBC), and liver biochemistry should be checked to determine the need for treatment or annual monitoring, according to the American Association for the Study of Liver Diseases 1, 2
If alkaline phosphatase (ALP) is elevated ≥1.5× upper limit of normal (ULN), PBC can be diagnosed with confidence based on the positive AMA (≥1:40) alone, without requiring liver biopsy, as recommended by the American Association for the Study of Liver Diseases 1
Approximately 50% of AMA-positive individuals present with normal liver biochemistry, representing early/asymptomatic PBC, according to the American Association for the Study of Liver Diseases 2

To rule out alternative diagnoses, check for autoimmune hepatitis (AIH) features by measuring ALT, AST, and IgG levels, as suggested by the European Association for the Study of the Liver 1, 3
A small minority (8-12%) of AIH patients are AMA-positive but have a hepatocellular pattern (elevated ALT/AST > ALP) with elevated IgG rather than IgM, according to the European Association for the Study of the Liver 1, 2
If ALT/AST is disproportionately elevated (>5× ULN) or IgG is >2× ULN, consider AIH overlap syndrome and obtain liver biopsy, as recommended by the European Association for the Study of the Liver 1
In the revised AIH diagnostic scoring system, a positive AMA subtracts 4 points from the AIH score, making AIH less likely, according to the International Autoimmune Hepatitis Group 4, 5, 6

If cholestatic enzymes are elevated (ALP ≥1.5× ULN), initiate ursodeoxycholic acid (UDCA) immediately at 13-15 mg/kg/day, as recommended by the American Association for the Study of Liver Diseases 1, 2
Liver biopsy is not required for diagnosis when AMA is positive with cholestatic enzymes, according to the American Association for the Study of Liver Diseases 1
Assess treatment response at 12 months using composite criteria: ALP <1.67× ULN, total bilirubin ≤ULN, and ALP decrease ≥15%, as suggested by the American Association for the Study of Liver Diseases 1

If liver biochemistry is normal, do not start UDCA treatment, and screen annually with ALP, GGT, ALT, AST, and total bilirubin, as recommended by the American Association for the Study of Liver Diseases 1, 2
If cholestatic enzyme elevation develops during monitoring, immediately initiate UDCA as described above, according to the American Association for the Study of Liver Diseases 1, 2
For symptom management, use cholestyramine as first-line treatment for pruritus, rifampicin as second-line, and naltrexone as third-line, as suggested by the American Association for the Study of Liver Diseases 1
Exclude confounding causes (hypothyroidism, anemia, sleep disorders) before attributing fatigue to PBC, according to the American Association for the Study of Liver Diseases 1